Pediatrix Medical price target lowered to $9 from $10 at Mizuho

Mizuho analyst Ann Hynes lowered the firm’s price target on Pediatrix Medical to $9 from $10 and keeps a Neutral rating on the shares. The analyst reduced estimates saying Pediatrixs volume was challenged in the quarter, resulting in a revenue miss. Given the challenging operating environment, coupled with the uncertainty around the platform transition, the firm does not expect meaningful earnings upside or multiple expansion from current levels.